Izalontamab brengitecan
Antibody–drug conjugate
Also known as BMS-986507
Evidence outlook
Approved: Adults with recurrent or metastatic esophageal squamous cell carcinoma after... (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 3 · investigational in the USNasopharyngeal Carcinoma · Phase 3 · investigational in the USEsophageal Squamous Cell Carcinoma · Phase 3 · investigational in the USOvarian Cancer · Phase 3 · investigational in the USBiliary Tract Cancer · Phase 3 · investigational in the USUrothelial Carcinoma · Phase 3 · investigational in the US
Also approved (2)
- Adults with recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy
- Recurrent or metastatic nasopharyngeal carcinoma after prior platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07100080 NCT07100080 · Non-Small Cell Lung Cancer Registry: NCT07100080 | 2/3 | Recommended Phase 3 Dose (RP3D) of BMS-986507 (Approximately 3 months after the first dose); Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR) (Up to 3 years) 2028-12-15 | In progress: results expected 15 Dec 2028 | not yet graded | link ↗ |
View 2 more trials
NCT07680790 NCT07680790 · Non-Small Cell Lung Cancer Registry: NCT07680790 | 3 | Progression-Free Survival (PFS) using blinded independent central review (BICR) assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) (Up to approximately 3 years) 2031-12-30 | In progress: results expected 30 Dec 2031 | not yet graded | link ↗ |
NCT06382129 NCT06382129 · Non-small Cell Lung Cancer Registry: NCT06382129 | 3 | Overall survival (OS) (Up to approximately 24 months) 2026-12 | In progress: results expected 1 Dec 2026 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (27)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other EGFR + HER3 drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Biliary Tract Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Izalontamab Brengitecan: this drug | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6) | |
| Zanidatamab | Approved | Multispecific antibody | HER2 | Weak signal | NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023) | |
| Futibatinib (Lytgobi) | Phase 3 | Small molecule | FGFR (FGFR1/2/3/4) | not yet graded | No reviewed efficacy summary in this indication | |
| Ivonescimab | Phase 3 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tovecimig | Phase 2/3 | Multispecific antibody | DLL4 x VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Phase 2 | Monoclonal antibody | VEGFR2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(55 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Izalontamab brengitecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (18)
November 2026 (1)
What to watch
December 2026 (17)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (14)
May 2027 (5)
What to watch
What to watch
What to watch
What to watch
June 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (1)
What to watch
September 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (9)
March 2028 (1)
What to watch
December 2028 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (6)
January 2029 (2)
December 2029 (4)
What to watch
What to watch
What to watch
What to watch
2030 (4)
2031 (2)
2032 (1)
December 2032 (1)
What to watch
2033 (1)
December 2033 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent